Myosin

Other Cytoskeletal Signaling Related Inhibitors

HSP Kinesin Microtubule Associated Integrin PAK Dynamin MLCK TACC3 Gap-Junction Actin

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S2623	Omecamtiv mecarbil (CK-1827452)	Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure, currently in Phase 2.	Nat Biotechnol, 2025, 10.1038/s41587-025-02725-6 Eur Heart J, 2025, ehaf813 Journal of General Physiology, 2025, e202513762
E6493^New	MT-125	MT-125 is a first-in-class, brain-penetrant small-molecule inhibitor of NMIIA with a Ki of 2.7 μM and NMIIB with an EC50 of 1.7 μM. It also exhibits significant preclinical activity in glioblastoma (GBM) models.

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S2623

Omecamtiv mecarbil (CK-1827452)

Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure, currently in Phase 2.

Nat Biotechnol, 2025, 10.1038/s41587-025-02725-6

Eur Heart J, 2025, ehaf813

Journal of General Physiology, 2025, e202513762

Verified customer review of Omecamtiv mecarbil (CK-1827452)

E6493^New

MT-125

MT-125 is a first-in-class, brain-penetrant small-molecule inhibitor of NMIIA with a Ki of 2.7 μM and NMIIB with an EC50 of 1.7 μM. It also exhibits significant preclinical activity in glioblastoma (GBM) models.